## Hilde Rosing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8676836/publications.pdf

Version: 2024-02-01

1478505 1720034 9 204 6 7 citations h-index g-index papers 9 9 9 506 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacology Research and Perspectives, 2015, 3, e00131.	2.4	127
2	Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. Mass Spectrometry Reviews, 2011, 30, 321-343.	5.4	28
3	Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. Cancer Chemotherapy and Pharmacology, 2012, 69, 1457-1466.	2.3	18
4	Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite βâ€'decitabine in human plasma, whole blood and urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1109, 132-141.	2.3	10
5	Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular l̂²-decitabine nucleotides and genomic DNA incorporated l̂²-decitabine and 5-methyl-2′-deoxycytidine. lournal of Pharmaceutical and Biomedical Analysis. 2019. 164. 16-26.	2.8	9
6	Facile Small Scale Synthesis of Nucleoside 5′-Phosphate Mixtures. Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 14-26.	1.1	6
7	Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer. Investigational New Drugs, 2020, 38, 1085-1095.	2.6	6
8	Quantitative LC-MS/MS analysis of 5-hydroxymethyl- $2\hat{a}\in^2$ -deoxyuridine to monitor the biological activity of J-binding protein. Analytical Biochemistry, 2020, 610, 113930.	2.4	0
9	Development and Validation of a Stability-indicating HPLC Method for the Analysis of Cabazitaxel in Jevtana® Concentrate-solvent Leftover Samples. Current Pharmaceutical Analysis, 2021, 17, 691-701.	0.6	O